Explore

Rapid Read Rapid Read
Otsuka to Present Key Findings from Phase 3 VISIONARY Trial on IgA Nephropathy at GlomCon Hawaii 2026

Otsuka to Present Key Findings from Phase 3 VISIONARY Trial on IgA Nephropathy at GlomCon Hawaii 2026

Otsuka Pharmaceutical Development & Commercialization, Inc. is set to present significant findings from its Phase 3 VISIONARY trial at the GlomCon Hawaii 2026 conference. The trial focuses on VOYXACT® (sibeprenlimab-szsi), a treatment for IgA nephropathy (IgAN), a chronic kidney disease. The study highlights the drug's ability to stabilize estimated glomerular filtration rate (eGFR) over two years, indicating its potential to preserve kidney function and halt disease progression. VOYXACT is the first U.S. FDA-approved selective APRIL inhibitor, targeting the underlying drivers of IgAN. The presentation will include detailed two-year eGFR and safety data, supporting Otsuka's ongoing submission for a supplemental Biologics License Application (sBLA) to the FDA for traditional approval.
Rapid Read Rapid Read
Nitinotes Completes First Study Procedures at Orlando Health in EASE IDE Trial for Obesity Treatment

Nitinotes Completes First Study Procedures at Orlando Health in EASE IDE Trial for Obesity Treatment

Nitinotes Ltd., a medical device company, has announced the completion of the first study procedures at Orlando Health as part of its pivotal U.S. EASE IDE trial. This trial is evaluating the safety and effectiveness of the EndoZip Automated Suturing System for Endoscopic Sleeve Gastroplasty (ESG), a minimally invasive procedure aimed at treating obesity. The procedures were conducted by Dr. Andre F. Teixeira and Dr. Manoel Galvao Neto, both prominent figures in bariatric surgery and endoscopic obesity care. The trial is designed to support a future U.S. FDA marketing submission. EndoZip, which has already received CE Mark approval in Europe, aims to simplify and standardize ESG, making it more accessible to physicians with varying levels of experience.
Trendline Trendline
Apnimed Plans $160M IPO to Fund Launch of Sleep Apnea Drug Oxnimbi

Apnimed Plans $160M IPO to Fund Launch of Sleep Apnea Drug Oxnimbi

Apnimed Plans $160M IPO to Fund Launch of Sleep Apnea Drug Oxnimbi
Trendline Trendline
UBS Analysts Issue New Ratings on Medical and Tech Stocks

UBS Analysts Issue New Ratings on Medical and Tech Stocks

UBS Analysts Issue New Ratings on Medical and Tech Stocks
Rapid Read Rapid Read
Pentagon to Test Blood Transfusion Payments for Civilian Ambulances to Save Lives

Pentagon to Test Blood Transfusion Payments for Civilian Ambulances to Save Lives

The Pentagon is launching a novel program through its TRICARE health insurance to test whether paying civilian ambulance providers for blood transfusions can improve trauma care outcomes. This five-year demonstration project aims to reimburse ground and air ambulance services for administering medically necessary blood transfusions to military personnel, family members, and retirees. The initiative is inspired by military practices developed during the wars in Iraq and Afghanistan, where blood transfusions were administered in prehospital settings to improve survival rates. The project seeks to address the current gap in trauma care, where many ambulances lack the capability to provide blood transfusions, especially in rural areas.
Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Rapid Read Rapid Read
Consolidated Food Supply Chains Linked to Worsening Cyclospora Outbreaks

Consolidated Food Supply Chains Linked to Worsening Cyclospora Outbreaks

The ongoing cyclospora outbreak in the U.S., which has affected thousands, is drawing attention to the centralized nature of the food supply chain. Experts suggest that the consolidation of food sourcing and distribution networks has turned isolated contamination events into widespread outbreaks. The cyclospora parasite's long incubation period and the challenges in tracking its path have exacerbated the situation. The FDA's investigation is focusing on shredded iceberg lettuce distributed by Taylor Farms, which reached multiple states. Experts argue that the industry's structure has amplified the outbreak's impact.
Rapid Read Rapid Read
U.S. Retailers Halt Mexican Produce Imports Amid Cyclospora Outbreak Concerns

U.S. Retailers Halt Mexican Produce Imports Amid Cyclospora Outbreak Concerns

Several major U.S. retailers and restaurants have ceased sourcing produce from central Mexico due to a cyclosporiasis outbreak linked to iceberg lettuce from Taylor Farms. The outbreak has resulted in 4,173 confirmed cases, with over 7,400 suspected cases, according to the U.S. Centers for Disease Control and Prevention. Former FDA Commissioner Scott Gottlieb highlighted that the outbreak might be connected to other produce like parsley and cilantro from the same region. The FDA's investigation suggests potential contamination from raw sewage due to weather conditions, though the exact cause remains under investigation. Taylor Farms has voluntarily suspended production and removed potentially affected products from the market.
Rapid Read Rapid Read
FDA Approves Freenome's SimpleScreen CRC Blood-Based Test for Colorectal Cancer Screening

FDA Approves Freenome's SimpleScreen CRC Blood-Based Test for Colorectal Cancer Screening

The U.S. Food and Drug Administration (FDA) has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer (CRC) in adults aged 45 and older who are at average risk. This test, which will be commercialized by Abbott in the U.S., offers a new option for CRC screening that requires only a simple blood draw. The approval follows extensive clinical research and collaboration, including the PREEMPT CRC study, which enrolled over 48,000 participants. SimpleScreen CRC demonstrated 81.1% sensitivity in detecting colorectal cancer and 90.4% specificity for advanced colorectal neoplasia. The test aims to increase screening rates among the estimated 60 million Americans overdue for CRC screening.
Trendline Trendline
Outlook Therapeutics Secures FDA Approval for AMD Drug Lytenava

Outlook Therapeutics Secures FDA Approval for AMD Drug Lytenava

Outlook Therapeutics Secures FDA Approval for AMD Drug Lytenava
Trendline Trendline
Neko Health's Full-Body Scan Gains Popularity Amid Wellness Trends

Neko Health's Full-Body Scan Gains Popularity Amid Wellness Trends

Neko Health's Full-Body Scan Gains Popularity Amid Wellness Trends
Trendline Trendline
Goldman Sachs Alternatives Acquires Majority Stake in Numantec for Global Expansion

Goldman Sachs Alternatives Acquires Majority Stake in Numantec for Global Expansion

Goldman Sachs Alternatives Acquires Majority Stake in Numantec for Global Expansion